Characteristics of 20 BMT patients with HC and 6 patients with significant BK viruria
Patients . | Sex/Age . | Disease . | Regimens . | BMT . | GVHD . | Day of engraftment . | |
---|---|---|---|---|---|---|---|
Overall grade . | Onset time3-150 . | ||||||
1 | F/40 | AML | Bu-Cy | Allo | 1 | 21 | 21 |
2 | M/39 | NHL | Cy-TBI | Allo | 0 | 24 | |
3 | M/27 | CML | Bu-Cy | Allo | 2 | 28 | 21 |
4 | M/42 | MM | Bu-Cy | Allo | 1 | 27 | 29 |
5 | F/25 | CML | Bu-Cy | Allo | 1 | 19 | 17 |
6 | F/30 | HD | BEAM | Auto | — | 11 | |
7 | M/50 | NHL | Bu-Cy | Allo | 3 | 24 | 20 |
8 | F/32 | HD | BEAM | Auto | — | 30 | |
9 | M/48 | AML | Bu-Cy | Allo | 2 | 22 | 19 |
10 | M/49 | AML | Bu-Cy | Allo | 0 | 19 | |
11 | M/42 | CML | Bu-Cy | Mud | 1 | 23 | 20 |
12 | F/40 | NHL | CBV | Allo | 1 | 21 | 20 |
13 | M/36 | CML | Bu-Cy | Allo | 1 | 27 | 24 |
14 | M/49 | MM | Fludara-TBI | Allo | 0 | 22 | |
15 | F/40 | AML | Bu-Cy | Mud | 2 | 28 | 25 |
16 | M/38 | CML | Bu-Cy | Mud | 1 | 42 | 25 |
17 | F/36 | CML | Bu-Cy | Allo | 1 | 21 | 20 |
18 | F/42 | Ca breast | CarboPEC | Auto | — | 13 | |
19 | F/46 | Ca breast | CarboPEC | Auto | — | 16 | |
20 | F/22 | ALL | Cy-TBI | Allo | 0 | 21 | |
21 | M/37 | AML | Bu-Cy | Mud | 0 | 23 | |
22 | M/27 | CML | Bu-Cy | Mud | 1 | 22 | 25 |
23 | M/67 | MM | Melphalan | Auto | — | 16 | |
24 | F/40 | AML | Bu-Cy | Allo | 4 | 35 | 21 |
25 | F/48 | CML | Bu-Cy | Allo | 1 | 21 | 14 |
26 | F/27 | NHL | Cy-TBI | Allo | 2 | 34 | 21 |
Patients . | Sex/Age . | Disease . | Regimens . | BMT . | GVHD . | Day of engraftment . | |
---|---|---|---|---|---|---|---|
Overall grade . | Onset time3-150 . | ||||||
1 | F/40 | AML | Bu-Cy | Allo | 1 | 21 | 21 |
2 | M/39 | NHL | Cy-TBI | Allo | 0 | 24 | |
3 | M/27 | CML | Bu-Cy | Allo | 2 | 28 | 21 |
4 | M/42 | MM | Bu-Cy | Allo | 1 | 27 | 29 |
5 | F/25 | CML | Bu-Cy | Allo | 1 | 19 | 17 |
6 | F/30 | HD | BEAM | Auto | — | 11 | |
7 | M/50 | NHL | Bu-Cy | Allo | 3 | 24 | 20 |
8 | F/32 | HD | BEAM | Auto | — | 30 | |
9 | M/48 | AML | Bu-Cy | Allo | 2 | 22 | 19 |
10 | M/49 | AML | Bu-Cy | Allo | 0 | 19 | |
11 | M/42 | CML | Bu-Cy | Mud | 1 | 23 | 20 |
12 | F/40 | NHL | CBV | Allo | 1 | 21 | 20 |
13 | M/36 | CML | Bu-Cy | Allo | 1 | 27 | 24 |
14 | M/49 | MM | Fludara-TBI | Allo | 0 | 22 | |
15 | F/40 | AML | Bu-Cy | Mud | 2 | 28 | 25 |
16 | M/38 | CML | Bu-Cy | Mud | 1 | 42 | 25 |
17 | F/36 | CML | Bu-Cy | Allo | 1 | 21 | 20 |
18 | F/42 | Ca breast | CarboPEC | Auto | — | 13 | |
19 | F/46 | Ca breast | CarboPEC | Auto | — | 16 | |
20 | F/22 | ALL | Cy-TBI | Allo | 0 | 21 | |
21 | M/37 | AML | Bu-Cy | Mud | 0 | 23 | |
22 | M/27 | CML | Bu-Cy | Mud | 1 | 22 | 25 |
23 | M/67 | MM | Melphalan | Auto | — | 16 | |
24 | F/40 | AML | Bu-Cy | Allo | 4 | 35 | 21 |
25 | F/48 | CML | Bu-Cy | Allo | 1 | 21 | 14 |
26 | F/27 | NHL | Cy-TBI | Allo | 2 | 34 | 21 |
Allo indicates allogeneic; MM, multiple myeloma; auto, autologous; HD, Hodgkin disease; Fludara, fludarabine; Ca breast, carcinoma of the breast; ALL, acute lymphocytic leukemia. Other abbreviations are explained in Table 1.
The onset time of GVHD refers to days after BMT.